Join Flagship for the Oncology Companion Diagnostics Xchange at hubXchange West. February 6-9, 2023. Attending hubXchange West? Meet with us to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program....
Visit Flagship at the SB-IO Summit.January 17-19, 2023. Attending the inaugural SB-IO Summit? Stop by our booth to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program. AI-powered digital pathology solutions...
Visit Flagship at ASH | Booth #1015. December 10-13, 2022. Attending ASH 2022? Stop by our booth to discuss how we can partner with you for end-to-end biomarker support. Discover our recently expanded services menu and pick up a map of our favorite New Orleans...
Visit Flagship at SITC | Booth #818.November 8-12, 2022.Stop by our booth to meet our new CSO Tom Turi, Ph.D., and talk with us about how we can partner with you for end-to-end biomarker support. Come learn about our new services, and pick up a map of our favorite...
Visit Flagship at World CB & CDx | Booth #4. Boston, MA | September 26-29, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support and see our latest data. Assay development and validation Clinical trial support...
Visit Flagship at AACR | Booth #1554. April 8-13, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support, see our latest data from this year’s featured posters, and pick up a map of our favorite NOLA eateries. Assay...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...
Acquisition significantly expands Flagship’s portfolio of biomarker and analytics servicesBroomfield, CO – August 31, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...
The journal Scientific Reports recently published a manuscript on the validation of Flagship’s new digital assay, Tissue Insight (TI) 22C3 NSCLC.1 This technology facilitates the otherwise cumbersome process of quantifying programmed cell death ligand 1 (PD-L1)...
PUBLICATIONS/POSTERS
Background Historically, immunohistochemistry (IHC) assays have been designed for simplicity of manual pathology, however, this is not always ideal to acquire the appropriate data for patient selection and outcomes. Due to various challenges within the current...
In the downloadable original research article sponsored by Pfizer, the digital tissue analysis was performed using the Flagship Biosciences proprietary Image Analysis platform. The article was published in the Journal: Clinical Cancer Research online first on June 3,...
In partnership with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, Flagship Biosciences published this downloadable original research article. It was first published on Monday, May 10...